Jasper Therapeutics Inc. (JSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 92,502 | 106,819 | 118,475 | 86,887 | 103,867 |
| TOTAL | $94,806 | $108,680 | $120,308 | $88,938 | $105,218 |
| Non-Current Assets | |||||
| PPE Net | 2,071 | 2,438 | 2,464 | 2,727 | 2,780 |
| Other Non-Current Assets | 2,536 | 2,811 | 3,191 | 3,227 | 2,407 |
| TOTAL | $4,607 | $5,249 | $5,655 | $5,954 | $5,187 |
| Total Assets | $99,413 | $113,929 | $125,963 | $94,892 | $110,405 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,086 | 2,964 | 2,391 | 4,149 | 3,256 |
| Accrued Expenses | 8,314 | 6,055 | 5,505 | 7,253 | 7,677 |
| Other current liabilities | N/A | 20 | 20 | N/A | 28 |
| TOTAL | $12,459 | $10,068 | $8,916 | $12,374 | $11,906 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 3,274 | 3,551 | 3,817 | 4,078 | 4,366 |
| TOTAL | $3,274 | $3,551 | $3,817 | $4,078 | $4,366 |
| Total Liabilities | $15,733 | $13,619 | $12,733 | $16,452 | $16,272 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 15,001 | 15,105 | 15,086 | 15,064 | 11,158 |
| Common Shares | 2 | 2 | 2 | 1 | 11 |
| Retained earnings | -216,548 | -197,911 | -183,328 | -169,600 | -153,019 |
| TOTAL | $83,680 | $100,310 | $113,230 | $78,440 | $94,133 |
| Total Liabilities And Equity | $99,413 | $113,929 | $125,963 | $94,892 | $110,405 |